Silence Therapeutics plc (SLN)

Market Cap	345.28M
Revenue (ttm)	27.17M
Net Income (ttm)	-79.13M
Shares Out	47.23M
EPS (ttm)	-1.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,188
Open	7.12
Previous Close	7.14
Day's Range	7.12 - 7.50
52-Week Range	1.97 - 18.32
Beta	1.38
Analysts	Buy
Price Target	39.67 (+442.68%)
Earnings Date	Nov 13, 2025

About SLN

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, includin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: SLN
• Website: https://www.silence-therapeutics.com

Financial Performance

In 2024, Silence Therapeutics's revenue was $43.26 million, an increase of 36.71% compared to the previous year's $31.64 million. Losses were -$45.31 million, -16.45% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for SLN stock is "Buy." The 12-month stock price target is $39.67, which is an increase of 442.68% from the latest price.

Price Target

$39.67

(442.68% upside)

Analyst Consensus: Buy